Australija - engleski - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - gadopentetate dimeglumine, quantity: 469.01 mg/ml - injection, solution - excipient ingredients: pentetate meglumine; meglumine; water for injections - indications as at 30 aug 1996: using magnetic resonance imaging (mri) dimeglumine gadopentetate provides contrast enhancement; in intracranial and spinal lesions in adults and children, including neonates and infants, with an abnormal blood-brain barrier, or abnormal vascularity; in whole body imaging in adult patients , including the neck region, the thoracic and abdominal space, the female breast, the pelvis and the musculoskeletal system. note: reliable enhancement is not provided in imaging the pancreas and the male reproductive organs (prostate, testis and penis).

Australija - engleski - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - gadopentetate dimeglumine, quantity: 469.01 mg/ml - injection, solution - excipient ingredients: meglumine; water for injections; pentetate meglumine - indications as at 30 august 1996: using magnetic resonance imaging (mri) dimeglumine gadopentetate provides contrast enhancement; in intracranial and spinal lesions in adults and children, including neonates and infants, with an abnormal blood-brain barrier, or abnormal vascularity; in whole body imaging in adult patients, including the neck region, the thoracic and abdominal space, the female breast, the pelvis and the musculoskeletal system. note: reliable enhancement is not provided in imaging the pancreas and the male reproductive organs (prostate, testis and penis).

Australija - engleski - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - gadopentetate dimeglumine, quantity: 469.01 mg/ml - injection, solution - excipient ingredients: water for injections; meglumine; pentetate meglumine - indications as at 30 august 1996: using magnetic resonance imaging (mri) dimeglumine gadopentetate provides contrast enhancement; in intracranial and spinal lesions in adults and children, including neonates and infants, with an abnormal blood-brain barrier, or abnormal vascularity; in whole body imaging in adult patients, including the neck region, the thoracic and abdominal space, the female breast, the pelvis and the musculoskeletal system. note: reliable enhancement is not provided in imaging the pancreas and the male reproductive organs (prostate, testis and penis).

Australija - engleski - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - gadopentetate dimeglumine, quantity: 469.01 mg/ml - injection, solution - excipient ingredients: meglumine; pentetate meglumine; water for injections - indications as 30 august 1996: using magnetic resonance imaging (mri) dimeglumine gadopentetate provides contrast enhancement; in intracranial and spinal lesions in adults and children, including neonates and infants, with an abnormal blood-brain barrier, or abnormal vascularity; in whole body imaging in adult patients, including the neck region, the thoracic and abdominal space, the female breast, the pelvis and the musculoskeletal system. note: reliable enhancement is not provided in imaging the pancreas and the male reproductive organs (prostate, testis and penis).

Australija - engleski - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - gadopentetate dimeglumine, quantity: 469.01 mg/ml - injection, solution - excipient ingredients: water for injections; meglumine; pentetate meglumine - indications as at 30 august 1996: using magnetic resonance imaging (mri) dimeglumine gadopentetate provides contrast enhancement; in intracranial and spinal lesions in adults and children, including neonates and infants, with an abnormal blood-brain barrier, or abnormal vascularity; in whole body imaging in adult patients , including the neck region, the thoracic and abdominal space, the female breast, the pelvis and the musculoskeletal system. note: reliable enhancement is not provided in imaging the pancreas and the male reproductive organs (prostate, testis and penis).

Australija - engleski - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - gadopentetate dimeglumine, quantity: 469.01 mg/ml - injection, solution - excipient ingredients: meglumine; water for injections; pentetate meglumine - using magnetic resonance imaging (mri) dimeglumine gadopentetate provides contrast enhancement: . in intracranial and spinal lesions in adults and children with abnormal blood-brain barrier, or abnormal vascularity; . in whole body imaging in adult patients, including the neck region, the thoracic and abdominal space, the female breast, the pelvis and the musculoskeletal system. note: reliable enhancement is not provided in imaging the pancreas and the male reproductive organs (prostate, testis and penis). indications as at 30 august 1996: using magnetic resonance imaging (mri), dimeglumine gadopentetate provides contrast enhancement; in intracranial and spinal lesions in adults and children, including neonates and infants, with an abnormal blood-brain barrier, or abnormal vascularity; in whole body imaging in adult patients, including the neck region, the thoracic and abdominal space, the female breast, the pelvis and the musculoskeletal system. note: reliable enhancement is not provided in imaging the pan

Kenija - engleski - Pharmacy and Poisons Board

unique pharmaceuticals ltd - gadopentetate dimeglumine injection usp - injection - gadopentetate dimeglumine 469 mg - gadopentetic acid

Kenija - engleski - Pharmacy and Poisons Board

unique pharmaceutical laboratories (a division of… plot no4, phase-iv, g.i.d.c. industrial area, - gadopentetate dimeglumine - injection - gadopentetate dimeglumine 469 mg - contrast media - magnetic resonance imaging:

Kenija - engleski - Pharmacy and Poisons Board

gadopentetate dimegluimne - injection - gadopentetate dimegluimne 469 mg - contrast media

Irska - engleski - HPRA (Health Products Regulatory Authority)

bayer limited - gadopentetate dimeglumine - solution for injection - 0.5 mmol/ml - paramagnetic contrast media